John Simard
| John Simard | |
|---|---|
| Born | John Simard 1961 (age 64–65) Montreal, Quebec |
| 🎓 Alma mater | University of Saskatchewan University of Toronto |
| 💼 Occupation | |
John Simard (born 1961) is a Canadian-born biotechnology entrepreneur and the founder and CEO of XBiotech.[1][2]
Early life and education
John Simard was born in 1961 in Montreal, Quebec, Canada.[1] He earned a biochemistry degree from the University of Saskatchewan in 1992, then pursued graduate studies in immunology at the University of Toronto's Department of Medical Biophysics.[3][4]
In 1994, Simard left his graduate program to work with Tak W. Mak at the Amgen Research Institute, where he co-authored a textbook on immunology with Mak.[4] He also co-authored a manuscript with Nobel Laureate Rolf Zinkernagel, focusing on the biology of cytotoxic T lymphocytes (CTL).[4]
Career
Simard began his career in biotechnology by establishing CTL Immunotherapies in 1997, a developer of therapeutic vaccines.[1][5] Later, he also founded AlleCure Corp. in Valencia, California, which developed allergy treatments and immune modulating therapies.[6][5] His first two companies were eventually merged with MannKind Corporation. Simard remained in MannKind as president of its immunology division and a member of the board of directors.[1][7][8]
In 2005, Simard founded XBiotech, which specializes in the research and development of human-derived antibody therapeutics for cancer, inflammatory and infectious diseases.[1][3]
Research
Simard has pioneered immunotherapies targeting interleukin 1-alpha, including a neutralizing antibody that was sold for a total of $1.35 billion in cash and potential milestone payments.[9][4] He holds over 300 issued and pending patents in areas such as cancer antigen identification, immunotherapies for cancer and infectious diseases, and techniques for identifying and cloning human antibodies.[4]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 https://www.bizjournals.com/austin/print-edition/2014/10/17/meet-john-simard-ceo-of-xbiotech.html
- ↑ https://www.bizjournals.com/austin/news/2020/06/11/austins-top-paid-ceos.html
- ↑ 3.0 3.1 "John Simard, Xbiotech USA Inc: Profile and Biography". Bloomberg.com.
- ↑ 4.0 4.1 4.2 4.3 4.4 "John Simard". XBiotech.
- ↑ 5.0 5.1 Rockwell, Lilly. "How Austin's XBiotech aims to revolutionize drug discovery". Austin American-Statesman.
- ↑ Institute, ERI Economic Research. "John Simard Salary Information 2022". ERI Economic Research Institute.
- ↑ "BIOTECH---Mann Slates Biotech IPO by Year End". 13 May 2001.
- ↑ https://www.bizjournals.com/austin/print-edition/2011/01/28/xbiotech-has-huge-plans.html
- ↑ https://www.bizjournals.com/austin/news/2020/02/10/1-35b-deal-offers-vindication-runway-for-austin.html
This article "John Simard" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:John Simard. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
